Steven Cohen's PTCT Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.22 M shares of PTC Therapeutics, Inc. (PTCT) worth $74.91 M, representing 0.13% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in PTCT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2019, adding 1.44 M shares. Largest reduction occurred in Q4 2019, reducing 1.14 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +156,500 | New Buy | 156,500 | $44.01 |
| Q4 2014 | +12,500 | Add 7.99% | 169,000 | $51.77 |
| Q1 2015 | -169,000 | Sold Out | 169,000 | $0.00 |
| Q2 2015 | +156,300 | New Buy | 156,300 | $48.13 |
| Q3 2015 | +270,500 | Add 173.06% | 426,800 | $26.70 |
| Q4 2015 | -426,800 | Sold Out | 426,800 | $0.00 |
| Q3 2016 | +10,200 | New Buy | 10,200 | $14.02 |
| Q4 2016 | -10,200 | Sold Out | 10,200 | $0.00 |
| Q1 2017 | +550,698 | New Buy | 550,698 | $9.84 |
| Q2 2017 | -526,998 | Reduce 95.70% | 23,700 | $18.31 |
| Q3 2017 | +376,300 | Add 1587.76% | 400,000 | $20.01 |
| Q4 2017 | -400,000 | Sold Out | 400,000 | $0.00 |
| Q3 2018 | +88,900 | New Buy | 88,900 | $47.00 |
| Q4 2018 | +1.38 M | Add 1547.71% | 1.46 M | $34.32 |
| Q1 2019 | +1.44 M | Add 98.35% | 2.91 M | $37.64 |
| Q2 2019 | -252,946 | Reduce 8.71% | 2.65 M | $45.00 |
| Q3 2019 | -263,840 | Reduce 9.95% | 2.39 M | $33.82 |
| Q4 2019 | -1.14 M | Reduce 47.85% | 1.25 M | $48.03 |
| Q1 2020 | -755,101 | Reduce 60.62% | 490,600 | $44.61 |
| Q2 2020 | +811,174 | Add 165.34% | 1.3 M | $50.74 |
| Q3 2020 | -205,945 | Reduce 15.82% | 1.1 M | $46.75 |
| Q4 2020 | -148,829 | Reduce 13.58% | 947,000 | $61.03 |
| Q1 2021 | -883,491 | Reduce 93.29% | 63,509 | $47.35 |
| Q2 2021 | +600,606 | Add 945.70% | 664,115 | $42.27 |
| Q3 2021 | -144,715 | Reduce 21.79% | 519,400 | $37.21 |
| Q4 2021 | -164,300 | Reduce 31.63% | 355,100 | $39.83 |
| Q1 2022 | -355,100 | Sold Out | 355,100 | $0.00 |
| Q4 2023 | +78,100 | New Buy | 78,100 | $27.56 |
| Q1 2024 | -78,100 | Sold Out | 78,100 | $0.00 |
| Q2 2024 | +26,700 | New Buy | 26,700 | $30.58 |
| Q3 2024 | +549,160 | Add 2056.78% | 575,860 | $37.10 |
| Q4 2024 | +867,502 | Add 150.64% | 1.44 M | $45.14 |
| Q1 2025 | -69,789 | Reduce 4.84% | 1.37 M | $50.96 |
| Q2 2025 | -1.37 M | Sold Out | 1.37 M | $0.00 |
| Q3 2025 | +1.22 M | New Buy | 1.22 M | $61.37 |
Steven Cohen's PTC Therapeutics Investment FAQs
Steven Cohen first purchased PTC Therapeutics, Inc. (PTCT) in Q3 2014, acquiring 156,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held PTC Therapeutics, Inc. (PTCT) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2019, adding 2,905,393 shares worth $109.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,220,642 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $74.91 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.13% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in PTC Therapeutics, Inc. (PTCT) was 2,905,393 shares, as reported at the end of Q1 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.